NCT07400952

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Glaukos Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Conditions

• Keratoconus

Interventions

Type	Name	Description
DRUG	GLK-221 Ophthalmic Solution	GLK-221 Ophthalmic Solution administered twice daily to both eyes
DRUG	Placebo Ophthalmic Solution	Placebo Ophthalmic Solution administered twice daily to both eyes

Timeline

• Start date: 2025-12-23
• Primary completion: 2027-04-01
• Completion: 2027-04-01
• First posted: 2026-02-10
• Last updated: 2026-02-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study